Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-48.26	-27.52	-19.03	-18.05	-14.79
Depreciation & Amortization	0.06	0.03	0.18	0.01	-
Stock-Based Compensation	15.31	8.14	0.5	0.46	1.53
Other Adjustments	5.05	-	0.03	0.07	0.72
Change in Receivables	-	-	0.04	0.07	-0.11
Changes in Accounts Payable	0.15	0.27	-0.5	0.06	-0.63
Changes in Accrued Expenses	1.4	0.42	-0.14	-0.32	2.08
Changes in Unearned Revenue	-	-	-	-	-2.33
Changes in Other Operating Activities	-1.49	-0.49	0.84	0.36	-0.78
Operating Cash Flow	-27.79	-19.15	-18.09	-17.35	-14.3
Capital Expenditures	-0.01	-	-0.01	-0.24	-
Purchases of Investments	-39.09	-60.46	-29.43	-20.73	-
Proceeds from Sale of Investments	41.6	23.45	41.1	4.96	-
Payments for Business Acquisitions	-0.44	-	-	-	-
Investing Cash Flow	2.05	-37	11.66	-16.01	-
Long-Term Debt Repaid	-	-	-	-0.25	-0.04
Net Long-Term Debt Issued (Repaid)	-	-	-	-0.25	-0.04
Issuance of Common Stock	108.46	103.48	8.54	0.04	41.21
Repurchase of Common Stock	-	-	-	-	-0.08
Net Common Stock Issued (Repurchased)	108.46	103.48	8.54	0.04	41.14
Other Financing Activities	-	-	-0.14	-	-
Financing Cash Flow	108.46	103.48	8.41	-0.2	41.09
Net Cash Flow	82.73	47.33	1.98	-33.56	26.8
Free Cash Flow	-27.8	-19.15	-18.1	-17.59	-14.3
FCF Margin	-	-	-6947.87%	-14253.37%	-461.11%
Free Cash Flow Per Share	-0.28	-0.81	-3.00	-4.17	-4.71
Levered Free Cash Flow	-48.16	-27.29	-18.67	-18.44	-16.48
Unlevered Free Cash Flow	-51.87	-28.36	-19.73	-18.26	-16.42

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q